Prof. Wei Lu 陆伟
Chief Physician, Professor
Department of Hepatobiliary Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Early diagnosis and non-surgical treatment of liver cancer. Management of viral hepatitis, alcoholic and non-alcoholic cirrhosis, autoimmune liver disease, portal hypertension, cirrhosis, and drug-induced liver injury.
Dr. Lu is a Chief Physician, Professor, and MD with a doctoral supervisor role. Dr. Lu holds a special government allowance and serves as Hospital Party Secretary. Positions include National Committee Member of the Chinese Medical Association Gastroenterology Branch.
Professional roles
- Member, Chinese Medical Association
- Standing Committee Member, Tianjin Hepatology Branch
- Vice Chair, Tianjin Imaging Technology Research Association
- Editorial Board Member, Tianjin Medical Journal and Practical Hepatology
Name order: in Chinese the family name comes first (Lu Wei). Papers usually list the name as Wei Lu or Lu W.
Selected publications
44 papers on PubMed matched by name and affiliation; 23 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer, 2024 (senior author): Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study. PubMed 38781433
- Acta Pharmacol Sin, 2024 (senior author): Inhibition of USP7 enhances CD8(+) T cell activity in liver cancer by suppressing PRDM1-mediated FGL1 upregulation. PubMed 38589688
- Acta Pharmacol Sin, 2023 (senior author): Heat shock protein family A member 8 serving as a co-activator of transcriptional factor ETV4 up-regulates PHLDA2 to promote the growth of liver cancer. PubMed 37474643
- Microb Ecol, 2023 (senior author): A Novel Bifidobacterium/Klebsiella Ratio in Characterization Analysis of the Gut and Bile Microbiota of CCA Patients. PubMed 38030815
- Hepatology, 2023 (senior author): Intratumoral microbial heterogeneity affected tumor immune microenvironment and determined clinical outcome of HBV-related HCC. PubMed 37114494
- Biomol Biomed, 2023 (senior author): Fc fragment of IgG binding protein is correlated with immune infiltration levels in hepatocellular carcinoma. PubMed 36803544
- Drug Resist Updat, 2023 (senior author): Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression. PubMed 37210811
- Cancer Med, 2023 (senior author): Comparison of the long-term outcomes of patients with hepatocellular carcinoma within the Milan criteria treated by ablation, resection, or transplantation. PubMed 36016484
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion